A patient-centric therapeutic paradigm uncouples prostate cancer suppression from systemic metabolic collapse
Ziqun Liu, Hanchu Ye, Haoran Hu, Wuhong Chen, Chen Wang, Yongfeng Yang, Xinran Yan, Longlong Chen, Yang Wang, Yumeng Yang, Chunqiao Sun, Yaqing Bai, Haiyang Hou, Xinan Wang, Jun Cao, , Zhenfei Li
This paper identifies metabolic dysregulation caused by abiraterone in prostate cancer patients and develops Lifehug-9892 to suppress tumors while preserving systemic metabolic health.
bioRxiv · Sep 2, 2026 · PreprintCancer Biology